LONDON (Alliance News) - AstraZeneca PLC on Thursday reported positive results from its trial of Calquence in patients with chronic lymphocytic leukaemia, a type of blood cancer.
The FTSE 100 pharmaceutical company said that the phase III ELEVATE-TN trial met its primary endpoint early.
The primary endpoint was the demonstration of "statistically-significant and clinically-meaningful" improvement in progression-free survival from the combination of Calquence and obinutuzumab against chemotherapy-based treatment of chlorambucil and obinutuzumab.
The trial also met a "key" secondary endpoint showing that Calquence monotherapy achieved a statistically-significant and clinically-meaningful improvement in progression-free survival compared to the chemotherapy and obinutuzumab regimen.
Furthermore, the safety and tolerability of Calquence was "consistent with its established profile", Astra said.
"These findings confirm the superiority of Calquence as a monotherapy and also in combination over standard-of-care treatments for chronic lymphocytic leukaemia," Jose Baselga, executive vice-president of Oncology research & development, said.
AstraZeneca shares were trading up 0.8% at 6,003.00 pence each early Thursday morning.
Astrazeneca (AZN)
